Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 19/20 | 0.57 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7474289 | 0.87 | P2RY12 (0.62) | P2RY12USP28 | |
| SCHEMBL7489214 | 0.86 | P2RY12 (0.63) | P2RY12USP28 | |
| SCHEMBL7002344 | 0.86 | P2RY12 (0.72) | P2RY12USP28 | |
| SCHEMBL13768966 | 0.85 | P2RY12 (0.38) | P2RY12 | |
| SCHEMBL13768436 | 0.84 | P2RY12 (0.37) | P2RY12USP28 | |
| SCHEMBL7515643 | 0.84 | P2RY12 (0.73) | P2RY12USP28 | |
| SCHEMBL7507775 | 0.84 | P2RY12 (0.73) | P2RY12USP28 | |
| SCHEMBL7003996 | 0.82 | P2RY12 (0.61) | P2RY12USP28 | |
| SCHEMBL13764368 | 0.82 | P2RY12 (0.53) | P2RY12USP28 | |
| SCHEMBL13768432 | 0.81 | P2RY12 (0.64) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566722-B2 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-28 | — | — | US | disclosed |
| US-20080108635-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108635-A1 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885USP28 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.